Physician profile

Ali Hasnie

Cardiovascular Disease · Milwaukee, WI

NPI 1225561897

$28,952.21

in general payments reported to CMS, 2019-2025

30 companies · $5,511 in 2025

The $5,511 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$8,503.93
Grant$7,735.04
Food and Beverage$5,647.20
Education$605.68
Consulting Fee$150.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Medtronic, INC. $7,817.83 2021-2025 Corevalve Evolut R, Onyx Frontier, In.Pact Admiral
Boston Scientific Corporation $6,163.85 2021-2025 Versacross Access Solution, General - Catheter, Opticross
Inari Medical, INC. $3,518.95 2022-2025 Ct Thrombectomy System Kit, Flowtriever Catheter, S
Philips North America LLC $3,266.36 2022-2025 Igt Devices Undivided, US Eq Undivided, Coronary Undivided
Penumbra, INC. $2,516.55 2022-2025 Indigo System
Abbott Laboratories $1,096.27 2021-2024 Thoratec Heartmate 3 Lvas Implant Kit, Ensite Precision, Ensite
Cook Medical LLC $594.26 2021-2023 Cook
Acist Medical Systems, INC. $416.89 2023-2024
Abiomed $308.83 2023-2025 Impella
W. L. Gore & Associates, INC. $306.31 2022-2025 Gore Cardioform Septal Occluder, Gore-Tex Vascular Graft
Irhythm Technologies, INC. $299.10 2024 Zio Monitor, Zio Xt Patch
Endologix LLC $294.62 2024-2025 Afx2 Bifurcated Endograft System, Endocross Device, Torus Stent Graft System
Astellas Pharma US INC $279.97 2021-2022
Heartflow, INC. $256.23 2023 Ffrct
Novartis Pharmaceuticals Corporation $205.18 2024
Show all 30 companies
CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $204.36 2022
E.R. Squibb & Sons, L.L.C. $177.99 2024-2025 Camzyos
Cardiovascular Systems INC. $172.44 2022
Shockwave Medical, INC $171.31 2021-2024 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $169.89 2023-2025 Lifevest
Astrazeneca Pharmaceuticals LP $126.70 2019-2025 Wainua
Amgen INC. $124.99 2022
Zoll Circulation INC $119.00 2024 Catheter, Therox Ds2 Console, Downstream Cartridge
Chiesi USA, INC. $72.00 2023 Kengreal
Cordis US Corp. $64.48 2022
Cvrx, INC. $61.61 2024 Barostim Neo System
Stryker Corporation $48.43 2025 Flowtriever, Ct Thrombectomy System Kit, Flowtriever Catheter, S
Edwards Lifesciences Corporation $45.89 2023-2024 Sapien 3 Ultra Resilia
Getinge USA Sales, LLC $26.53 2023 Cardiosave Hybrid, Type B Plug
Terumo Medical Corporation $25.39 2024 Glidesheath Slender, Metacross Otw

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ali Hasnie

$28,952.21

in general payments reported 2019-2025

Years
2019-2025
Top company
Medtronic, INC.
Context
The $5,511 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/5705744/ali-hasnie

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.